Understanding what makes key opinion leaders prefer one company’s
programs over another company’s can give you a considerable edge as you
design a marketing plan that includes valuable insight from these highly
influential physicians.
This
one-of-a-kind report is the result of our polling hundreds of KOLs in
Europe. This report gives you insight into what KOLs across key
therapeutic areas have told us about the following:
–
What companies run the best advisory boards and why
–
Acceptable honorarium levels
–
Factors KOLs consider when deciding whether or not to
attend a program
–
Preferred meeting focus and structure
–
Topics of key interest
–
Differences in perspectives of researchers vs. clinicians
For companies who are
interested in this same type of information on a global scale, a similar
report is available on KOL's perspectives on world class advisory boards
in the United States.
This one-of-a-kind report captures the
responses of over 100 practicing oncologists in the United States – as
they are asked to rate the effectiveness of leading oncology sales
forces in regard to the following attributes:
We not only capture the revealing survey
results, but PharmaForce digs deeper by conducting targeted interviews
with members of the “best” and “worst” performing sales forces to
uncover the reasons for their rankings.
This program analyzes in detail the marketing expenditures of leading
oncology franchises in the top five countries in Europe (i.e., France,
Germany, Italy, Spain and the United Kingdom). The key expenditures
benchmarked include: